Healio

Allosteric modulator nonsuperior to placebo in Parkinson’s disease

Please provide your email address to receive an email when new articles are posted on . Change from baseline in gait variability did not differ between groups, regardless of cognitive load. Treatment ...
Healio

Neurosterix launches with $63 million to advance allosteric modulator therapeutics

Please provide your email address to receive an email when new articles are posted on . A Swiss biopharmaceutical company announced its launch with $63 million in Series A financing for research and ...
EurekAlert!

Allosteric modulation of G protein-coupled receptors as a novel therapeutic strategy in neuropathic pain

This new article publication from Acta Pharmaceutica Sinica B, discusses allosteric modulation of G protein-coupled receptors as a novel therapeutic strategy in neuropathic pain. Neuropathic pain is a ...
Nasdaq

Bionomics Announces Update on the α7 Nicotinic Acetylcholine Receptor (nAChR) Positive Allosteric Modulator (PAM) Collaboration with MSD

ADELAIDE, Australia, and CAMBRIDGE, Mass., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in ...
Monthly Prescribing Reference

Negative Allosteric Modulator Candidate Misses Endpoints in Social Anxiety Disorder Trial

Neuphoria’s social anxiety disorder program will be discontinued based on the results from the AFFIRM-1 trial. Topline results were announced from a phase 3 trial evaluating BNC210 in patients with ...

Addex GABAB PAM Candidate Demonstrates Solid Anti-Tussive Activity in Bleomycin IPF-Related Chronic Cough Model

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 29, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ...
Seeking Alpha

Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy

NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced ...
Pharmabiz

Addex Therapeutics’ drug candidate GABAB PAM shows solid anti-tussive activity in bleomycin IPF-related chronic cough model

Addex Therapeutics’ drug candidate GABAB PAM shows solid anti-tussive activity in bleomycin IPF-related chronic cough model: Geneva, Switzerland Saturday, May 2, 2026, 18:00 Hrs ...